| Market Capitalization (Millions $) |
119 |
| Shares
Outstanding (Millions) |
37 |
| Employees |
81 |
| Revenues (TTM) (Millions $) |
41 |
| Net Income (TTM) (Millions $) |
-44 |
| Cash Flow (TTM) (Millions $) |
46 |
| Capital Exp. (TTM) (Millions $) |
0 |
Nanobiotix S A
Nanobiotix S is a French clinical-stage nanomedicine company that is pioneering a new approach to cancer therapy. The company's proprietary technology platform, NanoXray, uses nanoparticles to increase the efficacy of radiotherapy and other cancer treatment modalities.
NanoXray technology involves the use of nanoparticles made of hafnium oxide, a material that is able to absorb X-rays and release the energy in a controlled manner. When these nanoparticles are injected into a tumor, they accumulate within cancer cells and, when exposed to X-ray radiation, they generate a localized burst of radiation that increases the effectiveness of the treatment.
Nanobiotix S is currently developing a suite of products based on the NanoXray technology platform, including NBTXR3, which is a radioenhancer designed to be used in conjunction with radiotherapy for the treatment of solid tumors. The company is also exploring the potential of NanoXray in combination with other cancer therapies, such as immunotherapy.
In addition to its NanoXray technology, Nanobiotix S is also working on the development of a pipeline of other nanomedicines focused on oncology and other diseases. The company is committed to bringing its innovative technology to patients and improving outcomes for those fighting cancer.
Company Address: 60 rue de Wattignies Paris 75012
Company Phone Number: (0)1 40 26 04 70 Stock Exchange / Ticker: NASDAQ NBTX
|
6.94% 